Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
Move amid evidence of widespread reporting gaps
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Subscribe To Our Newsletter & Stay Updated
